http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2649565-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ced47191f0d1af6f9c955ce124b4da9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38ffd5c4f9dac1f7fdbf0b81da6af5f7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2008-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18ccec8b68e9f83644e26958d023a904 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b66180b81aa782bf4d084c898a1b8b4 |
| publicationDate | 2018-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2649565-T3 |
| titleOfInvention | Immunoglobulin G against anthrax toxins |
| abstract | Class G immunoglobulin (IgG) directed against the anthrax toxin protective antigen (PA), comprising: - a light chain variable region having an amino acid sequence represented by sequence SEQ ID No. 1 or having a amino acid sequence represented by sequence SEQ ID No. 1 and further comprising at least one mutation selected from: - none / A (1) in which an amino acid A has been added at position -4 of sequence SEQ ID N ° 1, that is, immediately before the rest # -3 if it exists, and by default immediately before the rest # -2, and by default immediately before the rest # -1, and by default immediately before of residue No. -1 - none / I (2) in which an amino acid L has been added at position -3 of sequence SEQ IDN ° 1, either immediately before residue No. -2 if it exists, and of by default, immediately before rest # -1, and by default, immediately before rest # 1 - none / Q (3) in which an amino acid Q has been added at position -2 of sequence SEQ ID No. 1, either immediately before residue No. -1 if it exists, and by default immediately before residue No. 1 - no / L (4) in which an amino acid L has been added at position -1 of the sequence SEQ ID No. 1, either immediately before the residue No. 1 - Y / S, in which the amino acid Y in position 10 of sequence SEQ ID No. 1 has been replaced by amino acid S-K / R, where amino acid K in position 14 of sequence SEQ ID No. 1 has been replaced by amino acid RH / R, where amino acid H at position 20 of sequence SEQ ID No. 1 has been replaced by amino acid R-L / V, where amino acid L at position 100 of sequence SEQ ID No. 1 has been replaced by amino acid V - a heavy chain variable region that has an amino acid sequence represented by sequence SEQ ID No. 2, or that has an amino acid sequence represented by sec uence SEQ ID No. 2 and further comprising at least one mutation selected from the following mutations: - none / Q (1) in which an amino acid Q has been added at position -6 of sequence SEQ ID No. 2, either immediately before rest N ° -5 if it exists, and by default immediately before rest N ° -4, and by default immediately before rest N ° -3, and by default immediately before rest N ° -2, and by default, immediately before residue No. -1, and by default, immediately before residue No. 1 - none / V (2) in which an amino acid V has been added at position - 5 of the sequence SEQ ID N ° 2, either immediately before the rest N ° -4 if it exists, and by default, immediately before the rest N ° -3, and by default, immediately before the rest N ° -2, and by default, immediately before the rest No. -1, and by default, immediately before the rest No. 1 - none / Q (3) in which an amino acid Q has been added at position -4 of sequence SEQ ID No. 2, i.e. immediately before residue No. -3 if it exists, and by default immediately before residue N . ° -2, and by default immediately before residue No. -1, and by default immediately before residue No. 1 - none / L (4) in which an amino acid L has been added at position -3 of the sequence SEQ ID N ° 2, either immediately before the rest N ° -2 if it exists, and by default, immediately before the rest N ° -1, and by default, immediately before the rest N ° 1 - none / Q (5) in which an amino acid Q has been added at position -2 of sequence SEQ ID No. 2, either immediately before residue No. -1 if it exists, and by default immediately before residue No. 1 - none / E (6) in which an amino acid E has been added at position -1 of the sequence SEQ ID N ° 2, well immediately before the rest N ° 1 - L / V, in which the amino acid L in the position n 5 of the sequence SEQ ID No. 2 has been replaced by the amino acid V-A / T, in which amino acid A at position 17 of the sequence SEQ ID No. 2 has been replaced by the amino acid T-A / T, where amino acid A at position 113 of sequence SEQ ID No. 2 has been replaced by amino acid T-V / L, where amino acid V at position 114 of sequence SEQ ID No. 2 has been replaced by the amino acid L |
| priorityDate | 2007-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 99.